High-volume energy drinks · Gap in direct evidence for increased clinical arrhythmia

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Clinical harms · MaterialsWhat is the original direction of the selected existing question?Required	The selected existing question is “Increased clinical arrhythmia,” distinguished from its subclaim verdict record. The original wording of the question about increased clinical events is retained. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new independent-claim certification, invented verdict or subclaim subdivision was made.	Exact subclaim wording, Korean/English text and question/record relationship	If the question changes, retain the original existing wording, previous complete version and change event separately.
2	Partly verified	Full text not readStored summary read	N02 · Clinical harms · MaterialsHow do the subclaim verdict and parent score/axes differ?Required	The subclaim is ?, with the note “The four-hour trial did not test clinical arrhythmia.” It has no score/status/axes fields. Parent D30, Caution and B/S/R1/I2/E-/B2/C0 are parent context. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Subclaim score/status/assessment axes are null; parent values are not inserted.	Actual subclaim grade/note, absent score/status/axes and parent D30	When evidence is updated, distinguish original value preservation from actual judgment events.
3	Partly verified	Full text not readStored summary read	N03 · Clinical harms · MaterialsWhat are the actual trial population and applicability boundaries?Required	The 2019 trial involved 34 healthy adults aged 18–40 without cardiovascular disease, hypertension, QT prolongation or regular medication use. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.	Healthy adults aged 18–40, baseline exclusions and selected population	Distinguish other population materials by baseline risk, medication, age and actual eligibility.
4	Partly verified	Full text not readStored summary read	N04 · Clinical harms · MaterialsWhat are the actual identity and duration of the research exposure?Required	The original exposure was a single intake of 946 mL of energy drink containing about 300–320 mg caffeine within one hour. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.	946 mL, about 300–320 mg caffeine and one exposure within one hour	Connect nominal/actual and product-specific exposure differences with the relevant outcome.
5	Partly verified	Full text not readStored summary read	N05 · Clinical harms · MaterialsWhat are the identity and composition differences of drinks A/B and placebo?Required	The stored review summary records investigators preparing commercial drinks in identical containers and participants consuming A, B and placebo separately. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.	Commercial products A/B, preparation in identical containers and placebo composition	If actual product materials are provided, distinguish caffeine, combined ingredients and placebo differences.
6	Partly verified	Full text not readStored summary read	N06 · Clinical harms · MaterialsHow do 240-minute measurements differ from long-term observation?Required	The 2019 trial measured QTc and blood pressure every 30 minutes through 240 minutes after a single exposure. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.	Measurements through 240 minutes, 30-minute intervals and acute time points	Distinguish actual observation durations of acute biomarkers and long-term clinical outcomes in follow-up materials.
7	Partly verified	Full text not readStored summary read	N07 · Clinical harms · MaterialsWhat are the sequence and analysis units of the crossover trial?Required	The recorded design is a randomized double-masked placebo-controlled crossover trial; the same participants underwent each drink condition. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.	A/B/placebo in the same 34 people, sequence allocation and carryover/period effects	When materials are supplemented, distinguish conditions/time points within the same person and crossover assumptions.
8	Unverified	Full text not readStored summary read	N08 · Clinical harms · MaterialsWhat are the common conditions and other exposures?Required	The stored review summary preserves a healthy population and acute comparison of three drinks. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.	Pre-visit caffeine/activity, meals, medication and measurement environment	Record actual common product-comparison conditions and other exposures together in follow-up materials.
9	Partly verified	Full text not readStored summary read	N09 · Clinical harms · MaterialsHow were double masking, measurement and interpretation implemented?Required	The original design is described as double-masked, with investigators preparing drinks in identical containers. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.	Roles masked, identical containers and ECG/blood-pressure collection	Connect actual masking by role and measurement processes to outcomes.
10	Partly verified	Full text not readStored summary read	N10 · Clinical harms · MaterialsWhat are the registration identifier and current registration-content status?Required	NCT03196908 appears in the first existing evidence record and research description. The 2017 citation has no separate registration identifier. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.	2019 NCT03196908 and registration history/plans	If registration materials are provided, distinguish the report, plans and actual reading scope.
11	Partly verified	Full text not readStored summary read	N11 · Clinical harms · MaterialsWhat are the bibliographies and source locations of the two reports?Required	R01 is Shah SA et al., 2019, J Am Heart Assoc 8:e011318, PMID 31137991. R02 is Fletcher EA et al., 2017, the same journal 6:e004448, PMID 28446495. There is one evidence group and two citations. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.	Shah 2019, Fletcher 2017, PMIDs and evidence/citations	When bibliography is supplemented, distinguish report identity, original results and change events.
12	Partly verified	Full text not readStored summary read	N12 · Clinical harms · MaterialsWhat is the scope of investigator overlap and Mayo blood-pressure replication?Required	The stored review summary states that 2017 involved overlapping investigators and was not independent replication; independent Mayo investigators replicated blood pressure only. Limited independent QTc replication is a historical description. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.	Identical/unknown cohorts, author overlap and independent QTc/BP distinction	Distinguish identical cohorts, investigator overlap, independent institutions and QTc/blood-pressure endpoint replication in new materials.
13	Partly verified	Full text not readStored summary read	N13 · Clinical harms · MaterialsWhat is the original scope of support and disclosed relationships?Required	The original record states University of the Pacific support, no reported energy-drink-company funding and Sachin A. Shah’s expert-witness history in caffeine energy-drink litigation. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.	2019 university support, unreported company funding and litigation expert-witness history	If disclosures are provided, distinguish reports, support types, external relationships and historical/current scope.
14	Partly verified	Full text not readStored summary read	N14 · Clinical harms · MaterialsHow are original dates, Korean/English text, corrections, axes and history retained?Required	The reference date is 2026-08-26, corrections are an empty array and deliberation an empty string. Complete stored review text preserves Korean/English content, synthesized summaries, verdict decisions, assessment axes and false flags. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.	2026-08-26, empty corrections/deliberation and parent/sibling context	If changed materials arise, distinguish the complete pre-change original, events, versions and separate application.
15	Partly verified	Full text not readStored summary read	N15 · Clinical harms · MaterialsWhich materials were actually read?Required	The complete preserved 2961 JSON and its two existing selections were read for preparation. Reading of each report’s summary is distinguished from unread external originals in each checklist. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.	Complete local JSON summary, report-specific material items and unread external originals	Distinguish public availability, access, acquisition, actual reading scope and dates for new materials.
16	Partly verified	Full text not readStored summary read	N16 · Clinical harms · MaterialsAre two checklists/material items distinguished from trials/participants?Required	The two existing questions have different scopes in the same complete stored summary. Connecting R01’s 34 people, A/B/placebo and time-point materials to both checklists creates no new participant or replication trial. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.	s0/s1, two reports, conditions/time points and null unique trial/participant totals	Connect additional reports by distinguishing identical/different populations, institutions and endpoints.
17	Partly verified	Full text not readStored summary read	N17 · Clinical harms · MaterialsWhat is connected when new materials become available?Required	The two existing questions are prepared separately in the same seven-column format. Each condition was saved/frozen first, with a separate application timestamp retained. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.	Conditions, originals, observations, corrections, reading and change events	Separate actual additions/changes into complete prior originals, events, condition versions/freezing, separate application and current handoff.
18	Unverified	Full text not readStored summary read	N18 · Clinical harms · MaterialsWhat is the direct definition of clinical arrhythmia?Required	The selected question is “Increased clinical arrhythmia”; the stored review note explicitly states that the four-hour trial did not test clinical arrhythmia. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Arrhythmia types, symptom/ECG verification, assessment criteria, baseline arrhythmia exclusions and occurrence definitions are unverified.	Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment	Retain a proposal to specify event types, verification levels, occurrence times and original populations in clinical-event materials.
19	Unverified	Full text not readStored summary read	N19 · Clinical harms · MaterialsDoes the QTc biomarker answer increased event occurrence?Required	QTc is an ECG marker of delayed ventricular repolarization. The parent states that QTc prolongation cannot immediately be called clinical-arrhythmia occurrence. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Connections/validation between biomarker changes and direct arrhythmia occurrence, and occurrence data by population/duration, are unverified.	Separation of delayed-repolarization biomarkers and direct clinical events	Retain a proposal to distinguish biomarkers, symptoms and verified events in actual clinical materials.
20	Unverified	Full text not readStored summary read	N20 · Clinical harms · MaterialsAre arrhythmia event counts and at-risk population denominators available?Required	The stored review summary records that arrhythmia, hospitalization and death were not tested. The 34 people are participants in the biomarker crossover trial. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Clinical-arrhythmia numerators, actual at-risk/condition-specific denominators, recurrent/first occurrences and person-time are unverified.	Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events	Retain a proposal to distinguish person counts, recurrent events, exposure conditions and risk periods in clinical materials.
21	Unverified	Full text not readStored summary read	N21 · Clinical harms · MaterialsHow do four-hour measurements differ from clinical-risk periods?Required	2019 measurements occurred every 30 minutes through 240 minutes after intake. The study is not recorded as sufficiently capturing subsequent clinical events. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Continuous event monitoring, emergency/hospitalization follow-up, post-exposure risk windows and long-term follow-up are unverified.	240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure	Retain a proposal to distinguish measurement times from actual event observation/verification periods.
22	Unverified	Full text not readStored summary read	N22 · Clinical harms · MaterialsWhat are the actual contrasts and adjustments for clinical events?Required	Original A/B/placebo comparisons concern QTc and blood pressure. Actual estimates comparing increased clinical arrhythmia are not provided in the stored review summary. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Clinical-event contrasts, baseline risk, caffeine/concurrent-exposure adjustment and crossover/observational-design models are unverified.	Verified energy-drink-versus-comparator arrhythmia effects and models	Retain a proposal to connect actual exposure, comparator populations, baseline risk and models with events in clinical materials.
23	Unverified	Full text not readStored summary read	N23 · Clinical harms · MaterialsAre arrhythmia effects, CIs and power provided?Required	Unreported 95% CIs and the 10-ms assumption in the stored review summary concern between-condition QTc comparisons. Clinical-arrhythmia effects/CIs were not provided. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Direct arrhythmia risk differences/RRs/HRs, CIs, power and minimum important differences are unverified.	Direct clinical-event effects, intervals, denominators and power	If direct clinical estimates are provided, connect measures, denominators, durations and uncertainty.
24	Unverified	Full text not readStored summary read	N24 · Clinical harms · MaterialsWhat are the prespecified and actual clinical-arrhythmia collection plans?Required	The original prespecified primary endpoint was QTc; the stored review summary explicitly states that clinical arrhythmia was not tested. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Prespecified arrhythmia endpoints, active/passive collection, surveillance plans, plan dates and actual implementation are unverified.	Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy	Retain a proposal to distinguish prespecified plans from actual collection and the scope of events tested in new materials.
25	Unverified	Full text not readStored summary read	N25 · Clinical harms · MaterialsHow do event missingness, non-collection and non-reporting differ?Required	Only the preserved description of untested arrhythmia in a biomarker trial was read this time. External original materials/supplementary tables are unread. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Distinctions among absent event collection, non-reporting, undetermined findings, observation loss and zero events, and direct materials, are unverified.	Actual clinical-event collection, observation loss and reporting level	Retain a proposal to distinguish actual non-occurrence of events from absent collection/follow-up in clinical materials.
26	Unverified	Full text not readStored summary read	N26 · Clinical harms · MaterialsAre hospitalization, death and symptoms separate outcomes?Required	The stored review summary states that arrhythmia, hospitalization and death were not directly tested. Symptom-occurrence values were not provided either. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Definitions, denominators and durations for symptoms, verified arrhythmia, emergency care/hospitalization and death are unverified.	Distinction among arrhythmia, palpitations/symptoms, hospitalization and death	Retain a proposal to record symptoms, diagnoses, healthcare use and death as separate event outcomes.
27	Unverified	Full text not readStored summary read	N27 · Clinical harms · MaterialsWhat are applicability gaps for patients, adolescents and long-term exposure?Required	The original 2019 population comprised healthy adults aged 18–40, excluding disease, hypertension, QT prolongation and regular medication use. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Direct arrhythmia materials for baseline arrhythmia/cardiovascular risk, adolescents, medication/mixed exposure, small doses and repeated/chronic intake are unverified.	Healthy young people, one high-volume exposure and other risks/durations	Retain a proposal to distinguish actual risk populations, exposures, durations, concurrent medication and events in clinical materials.
28	Unverified	Full text not readStored summary read	N28 · Clinical harms · MaterialsAre earlier QTc and independent blood-pressure descriptions direct arrhythmia replication?Required	2017 is an earlier bibliography with QTc prolongation direction; Mayo is a description of independent blood-pressure replication. The stored review summary has no independent replication results for direct arrhythmia occurrence. R01 R02	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Actual clinical-event collection, bibliography, samples and verification materials from earlier/separate trials, and independent direct arrhythmia research, are unverified.	Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials	Retain a proposal to distinguish biomarker replication, institutional independence and direct clinical-event replication in additional materials.
29	Unverified	Full text not readStored summary read	N29 · Clinical harms · MaterialsWhat is the scope of the original ? grade and untested-outcome note?Required	The selected grade is ?, with the note “The four-hour trial did not test clinical arrhythmia.” Parent D30 biomarker-harm context is retained in its original role. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Direct clinical occurrence, risks/CIs, testing and long-term materials are unverified. This preparation does not assess effects or grades.	Selected clinical-event question, original ? and gap in direct evidence	If new direct materials are provided, preserve original ? and originals/change events while distinguishing separate judgment and preparation.
30	Unverified	Full text not readStored summary read	H01 · Clinical harms · MaterialsAre biomarkers, harms and clinical-event collection distinguished?Supporting harm information	Original materials record QTc/BP time changes and no testing of arrhythmia/hospitalization/death. Direct materials for the selected clinical events are unverified. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.	QTc/BP testing, verified clinical events and adverse-event definitions	Retain a proposal to distinguish measured biomarkers, symptoms and verified events in follow-up materials.
31	Partly verified	Full text not readStored summary read	H02 · Clinical harms · MaterialsWhat are harm timing and actual exposure?Supporting harm information	Research exposure was 946 mL with about 300–320 mg caffeine within one hour; measurements covered 240 minutes. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.	Single research exposure, acute measurement and event-risk periods	Retain a proposal to distinguish exposure, testing times and clinical-event risk periods in harm materials.
32	Unverified	Full text not readStored summary read	H03 · Clinical harms · MaterialsHow do between-condition biomarker differences differ from clinical harm comparisons?Supporting harm information	The stored review summary records maximum QTc and blood-pressure time differences, while direct clinical arrhythmia/hospitalization/death comparisons were not tested. R01	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.	Biomarker outcomes for A/B/placebo and clinical-event comparisons	Retain a proposal to connect direct harm materials using event definitions, comparisons and intervals separate from biomarkers.
33	Partly verified	Full text not readStored summary read	H04 · Clinical harms · MaterialsWhat are safety and event denominators?Supporting harm information	The 34 people in the stored review summary are healthy adult crossover-trial participants; separate denominators for each event/safety analysis were not provided. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.	34 people and actual denominators by condition/time/event	Retain a proposal to distinguish person, condition, time-point and measurement/event denominators in originals.
34	Partly verified	Full text not readStored summary read	H05 · Clinical harms · MaterialsWhat are alternative harm factors and ingredient-specific attribution?Supporting harm information	Exposure was commercial energy drink with about 300–320 mg caffeine. The stored review summary preserves a whole-product comparison. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.	Caffeine, combined ingredients, baseline/concurrent exposures and relatedness	Retain a proposal to distinguish whole products, ingredient-specific attribution and alternative factors in direct harm materials.
35	Unverified	Full text not readStored summary read	H06 · Clinical harms · MaterialsAre unread, untested, unreported and zero events distinguished?Supporting harm information	Actual reading this time concerns preserved JSON summaries; the original description of untested clinical events is retained. R01 R02	Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.	Actual reading level, untested clinical endpoints and original reports	Only for provided materials, connect actual zero events, missingness, non-reporting and non-collection with locations/durations.
36	Partly verified	Full text not readStored summary read	H07 · Clinical harms · MaterialsAre harms across reports, conditions and two checklists protected from duplicate counting?Supporting harm information	Two checklists prepare different existing questions from the same stored 2961 summary. The 2017/2019 bibliographies involve overlapping investigators; actual participant overlap is unverified. R01 R02	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.	2017/2019, author overlap, conditions/time points and two questions in the same summary	Retain a proposal to distinguish repeated reports of the same event from different populations/new events in harm materials.
37	Partly verified	Full text not readStored summary read	H08 · Clinical harms · MaterialsWhat are safety gaps for long-term use and vulnerable populations?Supporting harm information	The parent emphasizes a single high-volume exposure in healthy young adults; the original safety status is Caution. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.	Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents	Retain a proposal to record direct materials together with actual exposure, population and observation duration.
38	Partly verified	Full text not readStored summary read	H09 · Clinical harms · MaterialsAre signals distinguished from direct causal or clinical confirmation?Supporting harm information	Original s0 is D for the no-QTc/BP-effect claim; s1 is ? for increased clinical arrhythmia. Biomarker signals and the gap in direct clinical events are retained separately. R01	Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.	Biomarker signals, original D, direct clinical ? and unverified information	Retain a proposal to distinguish observation, relatedness, direct clinical-effect levels and change events in additional materials.

No items match your search or filter.

38 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: 2019 biomarker trial: 34 healthy adults aged 18–40 without cardiovascular disease, hypertension, QT prolongation or regular medication use. Direct clinical-event populations/denominators are unverified.
Ingredient, formulation and route: Single intake within one hour of 946 mL of energy drink containing about 300–320 mg caffeine
Dose: Original research exposure: 946 mL, about 300–320 mg caffeine, one exposure within one hour. Actual composition/intake completion and long-term exposure are unverified; this is not dosing guidance.
Comparator: 2019 within-person crossover of commercial drinks A/B versus placebo. Placebo composition/caffeine, effective n by condition and model details are unverified. The 2017 energy-drink-versus-caffeine comparison is a separate qualitative bibliography.
Measured outcome: The selected question concerns directly increased clinical arrhythmia. Original grade ?, and no testing in the four-hour trial. Event definitions, verification, numerators/denominators, effects/intervals and direct follow-up are unverified.
Duration: 2019 measurements every 30 minutes through 240 minutes after intake. Crossover visits/washout and actual clinical-event/long-term-risk observation are unverified.
Questions outside this scope: Transferring QTc/blood-pressure biomarker changes to occurrence of clinical arrhythmia, hospitalization or death; Converting/calculating condition-specific QTc maxima into between-group differences or ± into CIs; Creating new blood-pressure quantities, clusters/conditions/denominators or zero clinical events; Interpreting the 10-ms power assumption as a clinical-arrhythmia threshold/effect; Copying 2019 n/effects/NCT/support disclosures to 2017/Mayo; Certifying author overlap as an identical cohort or earlier/blood-pressure descriptions as independent clinical-event replication; Summing participants/trials across two checklists, reports, conditions or time points; Creating long-term/small-dose/adolescent/disease-medication population benefits/harms or intake/prevention/treatment procedures

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Shah SA, et al. Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial. J Am Heart Assoc. 2019;8:e011318. PMID: 31137991.

PubMed

Material type: 2019 energy-drink A/B versus placebo biomarker crossover trial
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: Maximum Bazett-QTc changes: A +17.9±13.9 ms, B +19.6±15.8 ms, placebo +11.9±11.1 ms; overall P=.005; blood-pressure time interactions are separate. The original boundary states that direct clinical arrhythmia, hospitalization and death were not tested.
Record level: First existing evidence record / Parent QTc and blood-pressure biomarker outcomes
Study overlap and independent replication: Shah 2019 pivotal direct biomarker trial and Fletcher 2017 earlier report with overlapping investigators. Actual participant/registration relationships are unverified; an identical cohort is not established. Mayo blood-pressure replication is qualitative stored-summary context without a bibliography; no R03 is created. Two checklists/conditions/time points are not summed.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Locally preserved summary	Local copy acquired	Summary read	The relevant bibliography, results and scope in the complete stored summary were read for preparation; this is not external full-text reading.
External abstract	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the citation URL in the review summary is connected; no current abstract/access verification was made.
External full text	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the existing bibliographic link is connected; current full-text location, public availability and access are unverified.
Registration	Current publication and access unverified	Access not attempted; not acquired	Not read	Original NCT03196908 identity; content/history are currently unread.
Protocol	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item; file existence/public availability, definitions, hierarchy and dates are unverified.
Statistical analysis plan	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for crossover/conditions/time/missingness, contrasts and clinical collection scope.
Results, denominator and harm details	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for biomarkers, effective n by condition, intervals and direct clinical-endpoint collection; unread materials are not changed to zero events.
Support and interests	Current publication and access unverified	Access not attempted; not acquired	Not read	Report-specific support/roles/current relationships are unread; 2019 support descriptions are not copied as individual 2017 disclosures.

R02 · Fletcher EA, et al. Randomized Controlled Trial of High-Volume Energy Drink Versus Caffeine Consumption on ECG and Hemodynamic Parameters. J Am Heart Assoc. 2017;6:e004448. PMID: 28446495.

PubMed

Material type: Earlier 2017 energy-drink-versus-caffeine report with overlapping investigators
Materials actually read: Summary read; external materials not read
Findings recorded in the stored summary: The earlier 2017 trial with overlapping investigators has only energy-drink-versus-caffeine bibliography and a summary of QTc prolongation direction. Sample, values, registration and clinical-event collection are unverified.
Record level: Second report in the existing citations · Qualitative context of the parent counterview
Study overlap and independent replication: Shah 2019 pivotal direct biomarker trial and Fletcher 2017 earlier report with overlapping investigators. Actual participant/registration relationships are unverified; an identical cohort is not established. Mayo blood-pressure replication is qualitative stored-summary context without a bibliography; no R03 is created. Two checklists/conditions/time points are not summed.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Locally preserved summary	Local copy acquired	Summary read	The relevant bibliography, results and scope in the complete stored summary were read for preparation; this is not external full-text reading.
External abstract	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the citation URL in the review summary is connected; no current abstract/access verification was made.
External full text	Current publication and access unverified	Access not attempted; not acquired	Not read	Only the existing bibliographic link is connected; current full-text location, public availability and access are unverified.
Registration	Current publication and access unverified	Access not attempted; not acquired	Not read	2017 registration identifier is absent from the review summary; the 2019 identifier is not copied.
Protocol	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item; file existence/public availability, definitions, hierarchy and dates are unverified.
Statistical analysis plan	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for crossover/conditions/time/missingness, contrasts and clinical collection scope.
Results, denominator and harm details	Current publication and access unverified	Access not attempted; not acquired	Not read	Required material item for biomarkers, effective n by condition, intervals and direct clinical-endpoint collection; unread materials are not changed to zero events.
Support and interests	Current publication and access unverified	Access not attempted; not acquired	Not read	Report-specific support/roles/current relationships are unread; 2019 support descriptions are not copied as individual 2017 disclosures.

Report counts versus independent study counts

Shah 2019 pivotal direct biomarker trial and Fletcher 2017 earlier report with overlapping investigators. Actual participant/registration relationships are unverified; an identical cohort is not established. Mayo blood-pressure replication is qualitative stored-summary context without a bibliography; no R03 is created. Two checklists/conditions/time points are not summed.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What is the original direction of the selected existing question?

Required materials and conditions: Exact subclaim wording, Korean/English text and question/record relationship
Conditions for verification: Connect Exact subclaim wording, Korean/English text and question/record relationship to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not count trials, participants or clinical events twice because two existing checklists were prepared.
Why this condition is needed: Preparation condition retaining the original scope of Exact subclaim wording, Korean/English text and question/record relationship.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are our own design

N02 · How do the subclaim verdict and parent score/axes differ?

Required materials and conditions: Actual subclaim grade/note, absent score/status/axes and parent D30
Conditions for verification: Connect Actual subclaim grade/note, absent score/status/axes and parent D30 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not inherit parent D30 or historical cross-checks as a subclaim score, current content-review pass or new independence certification.
Why this condition is needed: Preparation condition retaining the original scope of Actual subclaim grade/note, absent score/status/axes and parent D30.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N03 · What are the actual trial population and applicability boundaries?

Required materials and conditions: Healthy adults aged 18–40, baseline exclusions and selected population
Conditions for verification: Connect Healthy adults aged 18–40, baseline exclusions and selected population to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not extend the healthy young population to adolescents, patients, regular medication users or all consumers.
Why this condition is needed: Preparation condition retaining the original scope of Healthy adults aged 18–40, baseline exclusions and selected population.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

N04 · What are the actual identity and duration of the research exposure?

Required materials and conditions: 946 mL, about 300–320 mg caffeine and one exposure within one hour
Conditions for verification: Connect 946 mL, about 300–320 mg caffeine and one exposure within one hour to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not calculate or create can counts, caffeine equivalents, safe limits or intake/manufacturing/dosing guidance.
Why this condition is needed: Preparation condition retaining the original scope of 946 mL, about 300–320 mg caffeine and one exposure within one hour.
Referenced methods: M03 §3.2.2–3.2.3; reverse labeling and test adaptations are Chamgap's own design

N05 · What are the identity and composition differences of drinks A/B and placebo?

Required materials and conditions: Commercial products A/B, preparation in identical containers and placebo composition
Conditions for verification: Connect Commercial products A/B, preparation in identical containers and placebo composition to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not use the 2017 caffeine-comparison title to verify that the 2019 placebo was caffeine-matched.
Why this condition is needed: Preparation condition retaining the original scope of Commercial products A/B, preparation in identical containers and placebo composition.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

N06 · How do 240-minute measurements differ from long-term observation?

Required materials and conditions: Measurements through 240 minutes, 30-minute intervals and acute time points
Conditions for verification: Connect Measurements through 240 minutes, 30-minute intervals and acute time points to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert four hours into sufficient clinical-event testing duration or long-term safety.
Why this condition is needed: Preparation condition retaining the original scope of Measurements through 240 minutes, 30-minute intervals and acute time points.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; Design-specific harm questions in M19 §19.2; Detailed temporal relationships are internally designed

N07 · What are the sequence and analysis units of the crossover trial?

Required materials and conditions: A/B/placebo in the same 34 people, sequence allocation and carryover/period effects
Conditions for verification: Connect A/B/placebo in the same 34 people, sequence allocation and carryover/period effects to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not sum A/B/placebo, repeated time points or two checklists as independent participants/trials.
Why this condition is needed: Preparation condition retaining the original scope of A/B/placebo in the same 34 people, sequence allocation and carryover/period effects.
Referenced methods: M08 §8.1–8.2.3; CHAMGAP adaptation; Distinction between studies and reports in M04 §4.6.1–4.6.2; Cohort/outcome connections are CHAMGAP adaptations

N08 · What are the common conditions and other exposures?

Required materials and conditions: Pre-visit caffeine/activity, meals, medication and measurement environment
Conditions for verification: Connect Pre-visit caffeine/activity, meals, medication and measurement environment to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not invent fasting/rest/restriction times or experimental/daily-life procedures absent from the stored review summary.
Why this condition is needed: Preparation condition retaining the original scope of Pre-visit caffeine/activity, meals, medication and measurement environment.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; Chamgap adaptation

N09 · How were double masking, measurement and interpretation implemented?

Required materials and conditions: Roles masked, identical containers and ECG/blood-pressure collection
Conditions for verification: Connect Roles masked, identical containers and ECG/blood-pressure collection to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not newly verify masking of all interpretations or absence of measurement errors solely from identical containers or a design label.
Why this condition is needed: Preparation condition retaining the original scope of Roles masked, identical containers and ECG/blood-pressure collection.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N10 · What are the registration identifier and current registration-content status?

Required materials and conditions: 2019 NCT03196908 and registration history/plans
Conditions for verification: Connect 2019 NCT03196908 and registration history/plans to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not copy the 2019 NCT as the 2017 registration identifier or upgrade identifier presence to registration verification/link checks.
Why this condition is needed: Preparation condition retaining the original scope of 2019 NCT03196908 and registration history/plans.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a and M04 §4.6.3; Chamgap application

N11 · What are the bibliographies and source locations of the two reports?

Required materials and conditions: Shah 2019, Fletcher 2017, PMIDs and evidence/citations
Conditions for verification: Connect Shah 2019, Fletcher 2017, PMIDs and evidence/citations to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not create an evidence group absent from the stored summary for R02 or infer DOI/PMCID from article numbers.
Why this condition is needed: Preparation condition retaining the original scope of Shah 2019, Fletcher 2017, PMIDs and evidence/citations.
Referenced methods: M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

N12 · What is the scope of investigator overlap and Mayo blood-pressure replication?

Required materials and conditions: Identical/unknown cohorts, author overlap and independent QTc/BP distinction
Conditions for verification: Connect Identical/unknown cohorts, author overlap and independent QTc/BP distinction to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not equate investigator overlap with an identical cohort or create R03/independent clinical-arrhythmia evidence from unspecified Mayo mentions.
Why this condition is needed: Preparation condition retaining the original scope of Identical/unknown cohorts, author overlap and independent QTc/BP distinction.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N13 · What is the original scope of support and disclosed relationships?

Required materials and conditions: 2019 university support, unreported company funding and litigation expert-witness history
Conditions for verification: Connect 2019 university support, unreported company funding and litigation expert-witness history to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not upgrade university support or unreported company funding to new independence certification, absence of conflicts or identical 2017 support.
Why this condition is needed: Preparation condition retaining the original scope of 2019 university support, unreported company funding and litigation expert-witness history.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N14 · How are original dates, Korean/English text, corrections, axes and history retained?

Required materials and conditions: 2026-08-26, empty corrections/deliberation and parent/sibling context
Conditions for verification: Connect 2026-08-26, empty corrections/deliberation and parent/sibling context to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not fill original grades, absences, empty values or historical cross-checks with new values/current completed review.
Why this condition is needed: Preparation condition retaining the original scope of 2026-08-26, empty corrections/deliberation and parent/sibling context.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

N15 · Which materials were actually read?

Required materials and conditions: Complete local JSON summary, report-specific material items and unread external originals
Conditions for verification: Connect Complete local JSON summary, report-specific material items and unread external originals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert original citation links, historical paper descriptions or copies into external full-text reading/successful access.
Why this condition is needed: Preparation condition retaining the original scope of Complete local JSON summary, report-specific material items and unread external originals.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N16 · Are two checklists/material items distinguished from trials/participants?

Required materials and conditions: s0/s1, two reports, conditions/time points and null unique trial/participant totals
Conditions for verification: Connect s0/s1, two reports, conditions/time points and null unique trial/participant totals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not add two checklists/reports/crossover conditions or 34-person values to create an independent total sample.
Why this condition is needed: Preparation condition retaining the original scope of s0/s1, two reports, conditions/time points and null unique trial/participant totals.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; design-specific adaptation is Chamgap’s own design

N17 · What is connected when new materials become available?

Required materials and conditions: Conditions, originals, observations, corrections, reading and change events
Conditions for verification: Connect Conditions, originals, observations, corrections, reading and change events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Original candidate pending/eligibility indications are historical; do not reactivate them as active review/waiting.
Why this condition is needed: Preparation condition retaining the original scope of Conditions, originals, observations, corrections, reading and change events.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

N18 · What is the direct definition of clinical arrhythmia?

Required materials and conditions: Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment
Conditions for verification: Connect Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert QTc prolongation, blood-pressure signals or assumed palpitations into actual arrhythmia diagnoses.
Why this condition is needed: Preparation condition retaining the original scope of Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

N19 · Does the QTc biomarker answer increased event occurrence?

Required materials and conditions: Separation of delayed-repolarization biomarkers and direct clinical events
Conditions for verification: Connect Separation of delayed-repolarization biomarkers and direct clinical events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert biomarker P values/means/the 10-ms assumption into clinical-arrhythmia effects or event counts.
Why this condition is needed: Preparation condition retaining the original scope of Separation of delayed-repolarization biomarkers and direct clinical events.
Referenced methods: M03 §3.2.4; internally defined extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

N20 · Are arrhythmia event counts and at-risk population denominators available?

Required materials and conditions: Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events
Conditions for verification: Connect Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert untested outcomes into zero events or copy 34 as a verified arrhythmia denominator.
Why this condition is needed: Preparation condition retaining the original scope of Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptations are designed by CHAMGAP; M19 §19.1.2–19.2.4; CHAMGAP adaptation

N21 · How do four-hour measurements differ from clinical-risk periods?

Required materials and conditions: 240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure
Conditions for verification: Connect 240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert four-hour test markers into completed clinical-event testing or absence of long-term events.
Why this condition is needed: Preparation condition retaining the original scope of 240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure.
Referenced methods: Design-specific harm questions in M19 §19.2; Detailed temporal relationships are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP

N22 · What are the actual contrasts and adjustments for clinical events?

Required materials and conditions: Verified energy-drink-versus-comparator arrhythmia effects and models
Conditions for verification: Connect Verified energy-drink-versus-comparator arrhythmia effects and models to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not transfer biomarker A/B pairwise P values or caffeine content to between-condition clinical-event effects.
Why this condition is needed: Preparation condition retaining the original scope of Verified energy-drink-versus-comparator arrhythmia effects and models.
Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; CHAMGAP adaptation; M08 §8.2.2, M15 §15.3.1; CHAMGAP adaptation

N23 · Are arrhythmia effects, CIs and power provided?

Required materials and conditions: Direct clinical-event effects, intervals, denominators and power
Conditions for verification: Connect Direct clinical-event effects, intervals, denominators and power to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not calculate arrhythmia effects/CIs/risk rates from the QTc 10-ms assumption, ±, P values or n.
Why this condition is needed: Preparation condition retaining the original scope of Direct clinical-event effects, intervals, denominators and power.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design

N24 · What are the prespecified and actual clinical-arrhythmia collection plans?

Required materials and conditions: Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy
Conditions for verification: Connect Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not inherit primary QTc or an NCT identifier as prespecified/actually tested clinical arrhythmia.
Why this condition is needed: Preparation condition retaining the original scope of Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

N25 · How do event missingness, non-collection and non-reporting differ?

Required materials and conditions: Actual clinical-event collection, observation loss and reporting level
Conditions for verification: Connect Actual clinical-event collection, observation loss and reporting level to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not convert currently unread/untested materials into failed access, zero arrhythmias or confirmed increased arrhythmia.
Why this condition is needed: Preparation condition retaining the original scope of Actual clinical-event collection, observation loss and reporting level.
Referenced methods: M08 §8.2.2 and M15 §15.3.1: in-house application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4: design-specific adaptation is in-house.

N26 · Are hospitalization, death and symptoms separate outcomes?

Required materials and conditions: Distinction among arrhythmia, palpitations/symptoms, hospitalization and death
Conditions for verification: Connect Distinction among arrhythmia, palpitations/symptoms, hospitalization and death to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not assume symptoms to create new events or sum event types into a composite occurrence rate.
Why this condition is needed: Preparation condition retaining the original scope of Distinction among arrhythmia, palpitations/symptoms, hospitalization and death.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; CHAMGAP’s interpretation boundary, informed by M19 principles; no official causality tool was run

N27 · What are applicability gaps for patients, adolescents and long-term exposure?

Required materials and conditions: Healthy young people, one high-volume exposure and other risks/durations
Conditions for verification: Connect Healthy young people, one high-volume exposure and other risks/durations to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not newly establish/create clinical harms/safety, prevention/treatment or intake-care guidance for populations outside the trial.
Why this condition is needed: Preparation condition retaining the original scope of Healthy young people, one high-volume exposure and other risks/durations.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap’s own design; M03 §3.2.1; detailed population conditions are Chamgap’s own design

N28 · Are earlier QTc and independent blood-pressure descriptions direct arrhythmia replication?

Required materials and conditions: Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials
Conditions for verification: Connect Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not transfer earlier overlapping-investigator or independent blood-pressure descriptions into independently established increased clinical arrhythmia.
Why this condition is needed: Preparation condition retaining the original scope of Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; CHAMGAP adaptation; Distinction between studies and reports in M04 §4.6.1–4.6.2; Cohort/outcome connections are CHAMGAP adaptations

N29 · What is the scope of the original ? grade and untested-outcome note?

Required materials and conditions: Selected clinical-event question, original ? and gap in direct evidence
Conditions for verification: Connect Selected clinical-event question, original ? and gap in direct evidence to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Required
Application exceptions: Do not copy parent D in place of the selected ? or display the question “Increased clinical arrhythmia” as a confirmed observed conclusion.
Why this condition is needed: Preparation condition retaining the original scope of Selected clinical-event question, original ? and gap in direct evidence.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed

H01 · Are biomarkers, harms and clinical-event collection distinguished?

Required materials and conditions: QTc/BP testing, verified clinical events and adverse-event definitions
Conditions for verification: Connect QTc/BP testing, verified clinical events and adverse-event definitions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not convert biomarker worsening into clinical-event counts or untested outcomes into zero adverse events.
Why this condition is needed: Preparation condition retaining the original scope of QTc/BP testing, verified clinical events and adverse-event definitions.
Referenced methods: M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

H02 · What are harm timing and actual exposure?

Required materials and conditions: Single research exposure, acute measurement and event-risk periods
Conditions for verification: Connect Single research exposure, acute measurement and event-risk periods to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not convert the original exposure into recommended intake, a safe dose or prevention/treatment methods.
Why this condition is needed: Preparation condition retaining the original scope of Single research exposure, acute measurement and event-risk periods.
Referenced methods: M19 §19.2 design-specific harm questions; timing details are Chamgap-designed

H03 · How do between-condition biomarker differences differ from clinical harm comparisons?

Required materials and conditions: Biomarker outcomes for A/B/placebo and clinical-event comparisons
Conditions for verification: Connect Biomarker outcomes for A/B/placebo and clinical-event comparisons to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not transfer biomarker P values to clinical-harm P values or between-condition event risks.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker outcomes for A/B/placebo and clinical-event comparisons.
Referenced methods: M19 §§19.2.2–19.2.4 and M03 §3.2.3; Chamgap adaptation

H04 · What are safety and event denominators?

Required materials and conditions: 34 people and actual denominators by condition/time/event
Conditions for verification: Connect 34 people and actual denominators by condition/time/event to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not multiply crossover conditions/time measurements into participant counts or calculate risk rates from unread materials.
Why this condition is needed: Preparation condition retaining the original scope of 34 people and actual denominators by condition/time/event.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3 and M19 §§19.1.2–19.2.4; design-specific adaptation is Chamgap-designed

H05 · What are alternative harm factors and ingredient-specific attribution?

Required materials and conditions: Caffeine, combined ingredients, baseline/concurrent exposures and relatedness
Conditions for verification: Connect Caffeine, combined ingredients, baseline/concurrent exposures and relatedness to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not attribute every signal to caffeine alone or established harm from a particular ingredient, or invent mechanisms/event cases.
Why this condition is needed: Preparation condition retaining the original scope of Caffeine, combined ingredients, baseline/concurrent exposures and relatedness.
Referenced methods: M19 §§19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap-designed

H06 · Are unread, untested, unreported and zero events distinguished?

Required materials and conditions: Actual reading level, untested clinical endpoints and original reports
Conditions for verification: Connect Actual reading level, untested clinical endpoints and original reports to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not convert currently unread materials into zero side effects, failed access, an absent paper or confirmed direct clinical harm.
Why this condition is needed: Preparation condition retaining the original scope of Actual reading level, untested clinical endpoints and original reports.
Referenced methods: M19 §§19.1.2–19.2.4 and M04 §4.6.3; Chamgap adaptation

H07 · Are harms across reports, conditions and two checklists protected from duplicate counting?

Required materials and conditions: 2017/2019, author overlap, conditions/time points and two questions in the same summary
Conditions for verification: Connect 2017/2019, author overlap, conditions/time points and two questions in the same summary to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not equate investigator overlap with the same cohort or count two bibliographies/checklists as new independent-event replication.
Why this condition is needed: Preparation condition retaining the original scope of 2017/2019, author overlap, conditions/time points and two questions in the same summary.
Referenced methods: M04 §§4.6.1–4.6.2; harm-material adaptation is Chamgap-designed; M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

H08 · What are safety gaps for long-term use and vulnerable populations?

Required materials and conditions: Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents
Conditions for verification: Connect Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not create safe-dose, intake/care, arrhythmia prevention/treatment or medical-replacement procedures.
Why this condition is needed: Preparation condition retaining the original scope of Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation

H09 · Are signals distinguished from direct causal or clinical confirmation?

Required materials and conditions: Biomarker signals, original D, direct clinical ? and unverified information
Conditions for verification: Connect Biomarker signals, original D, direct clinical ? and unverified information to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Requirement and applicability: Supporting harm information
Application exceptions: Do not label original question wording as proven observation or combine biomarkers and clinical events into a new harm assessment.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker signals, original D, direct clinical ? and unverified information.
Referenced methods: Chamgap interpretive boundary informed by M19 principles; no formal causality tool was run

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Methodological principles stated in existing pilot materials and condition templates were referenced. The methodological text was not reviewed again in this work.

What the statuses mean

Met: The original content has been reviewed as meeting the conditions. This status is not used in this preparation.
Partly verified: Some information in the stored summary was linked during preparation; clinical verification or review is not complete.
Unverified: Required direct values, definitions or materials have not been established within the current storage and reading scope. This does not mean zero effect, no papers or failed access.
Review incomplete: Review of existing content or actual review incomplete.
Not reported: Used only when original materials were actually read and the outcome was judged unreported. Not used for external materials unread in this work.
Inaccessible: Used only when an actual access attempt has a recorded failure. Not used for access that was not attempted in this work.
Insufficient evidence for the conditions: Indicates insufficient direct materials for the relevant scope or conditions; it is not a new grade.
Not applicable: Used when the reason it does not apply to the original question is stated.
Conflicting data: Retains the scope of conflicting statements in original materials; it is not an arbitrary reassessment.

Change history

2026-10-12 · Public page/material version 1.0

Public reader pages and materials were prepared from the existing 38 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What is the original direction of the selected existing question?

Current findings: The selected existing question is “Increased clinical arrhythmia,” distinguished from its subclaim verdict record. The original wording of the question about increased clinical events is retained.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new independent-claim certification, invented verdict or subclaim subdivision was made.
Reason for missing information: No new independent-claim certification, invented verdict or subclaim subdivision was made.
Required materials and conditions: Exact subclaim wording, Korean/English text and question/record relationship
Materials to obtain first: Selected existing verdict record and complete parent summary
Further research: If the question changes, retain the original existing wording, previous complete version and change event separately.
Remaining uncertainty: Preparation scope of the stored summary. No new independent-claim certification, invented verdict or subclaim subdivision was made.
Conditions for verification: Connect Exact subclaim wording, Korean/English text and question/record relationship to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Exact subclaim wording, Korean/English text and question/record relationship.
Application exceptions: Do not count trials, participants or clinical events twice because two existing checklists were prepared.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are our own design

Related sources R01

N02 · How do the subclaim verdict and parent score/axes differ?

Current findings: The subclaim is ?, with the note “The four-hour trial did not test clinical arrhythmia.” It has no score/status/axes fields. Parent D30, Caution and B/S/R1/I2/E-/B2/C0 are parent context.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Subclaim score/status/assessment axes are null; parent values are not inserted.
Reason for missing information: Subclaim score/status/assessment axes are null; parent values are not inserted.
Required materials and conditions: Actual subclaim grade/note, absent score/status/axes and parent D30
Materials to obtain first: Original subclaim record and parent grade/score/axes and assessment history
Further research: When evidence is updated, distinguish original value preservation from actual judgment events.
Remaining uncertainty: Preparation scope of the stored summary. Subclaim score/status/assessment axes are null; parent values are not inserted.
Conditions for verification: Connect Actual subclaim grade/note, absent score/status/axes and parent D30 to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Actual subclaim grade/note, absent score/status/axes and parent D30.
Application exceptions: Do not inherit parent D30 or historical cross-checks as a subclaim score, current content-review pass or new independence certification.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources R01

N03 · What are the actual trial population and applicability boundaries?

Current findings: The 2019 trial involved 34 healthy adults aged 18–40 without cardiovascular disease, hypertension, QT prolongation or regular medication use.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.
Reason for missing information: Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.
Required materials and conditions: Healthy adults aged 18–40, baseline exclusions and selected population
Materials to obtain first: Recruitment/baseline characteristics, eligibility and outcome-specific flow
Further research: Distinguish other population materials by baseline risk, medication, age and actual eligibility.
Remaining uncertainty: Preparation scope of the stored summary. Detailed recruitment, sex, baseline QTc/blood pressure, caffeine habits, inclusion/exclusion and actual outcome population n are unverified.
Conditions for verification: Connect Healthy adults aged 18–40, baseline exclusions and selected population to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Healthy adults aged 18–40, baseline exclusions and selected population.
Application exceptions: Do not extend the healthy young population to adolescents, patients, regular medication users or all consumers.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

Related sources R01

N04 · What are the actual identity and duration of the research exposure?

Current findings: The original exposure was a single intake of 946 mL of energy drink containing about 300–320 mg caffeine within one hour.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.
Reason for missing information: Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.
Required materials and conditions: 946 mL, about 300–320 mg caffeine and one exposure within one hour
Materials to obtain first: Product composition, actual exposure, intake completion and crossover records
Further research: Connect nominal/actual and product-specific exposure differences with the relevant outcome.
Remaining uncertainty: Preparation scope of the stored summary. Actual individual intake/completion, full composition, batches, other exposure and adherence are unverified.
Conditions for verification: Connect 946 mL, about 300–320 mg caffeine and one exposure within one hour to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 946 mL, about 300–320 mg caffeine and one exposure within one hour.
Application exceptions: Do not calculate or create can counts, caffeine equivalents, safe limits or intake/manufacturing/dosing guidance.
Referenced methods: M03 §3.2.2–3.2.3; reverse labeling and test adaptations are Chamgap's own design

Related sources R01

N05 · What are the identity and composition differences of drinks A/B and placebo?

Current findings: The stored review summary records investigators preparing commercial drinks in identical containers and participants consuming A, B and placebo separately.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.
Reason for missing information: Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.
Required materials and conditions: Commercial products A/B, preparation in identical containers and placebo composition
Materials to obtain first: Trial product/placebo composition, preparation and distinguishability
Further research: If actual product materials are provided, distinguish caffeine, combined ingredients and placebo differences.
Remaining uncertainty: Preparation scope of the stored summary. Brands, quantities of A/B ingredients, placebo caffeine/calories/sugar, matching taste/appearance and separate effects of non-caffeine ingredients are unverified.
Conditions for verification: Connect Commercial products A/B, preparation in identical containers and placebo composition to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Commercial products A/B, preparation in identical containers and placebo composition.
Application exceptions: Do not use the 2017 caffeine-comparison title to verify that the 2019 placebo was caffeine-matched.
Referenced methods: M03 §3.2.2–3.2.3; Reverse-direction labels and assessment adaptation are Chamgap design; M03 §3.2.3 and M08 §8.2.2–8.2.3; Chamgap application

Related sources R01

N06 · How do 240-minute measurements differ from long-term observation?

Current findings: The 2019 trial measured QTc and blood pressure every 30 minutes through 240 minutes after a single exposure.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.
Reason for missing information: Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.
Required materials and conditions: Measurements through 240 minutes, 30-minute intervals and acute time points
Materials to obtain first: Visit/washout schedule, outcome collection and event follow-up scope
Further research: Distinguish actual observation durations of acute biomarkers and long-term clinical outcomes in follow-up materials.
Remaining uncertainty: Preparation scope of the stored summary. Intervals/washout between crossover visits, complete actual follow-up, subsequent event collection and repeated/long-term intake are unverified.
Conditions for verification: Connect Measurements through 240 minutes, 30-minute intervals and acute time points to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Measurements through 240 minutes, 30-minute intervals and acute time points.
Application exceptions: Do not convert four hours into sufficient clinical-event testing duration or long-term safety.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; Design-specific harm questions in M19 §19.2; Detailed temporal relationships are internally designed

Related sources R01

N07 · What are the sequence and analysis units of the crossover trial?

Current findings: The recorded design is a randomized double-masked placebo-controlled crossover trial; the same participants underwent each drink condition.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.
Reason for missing information: Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.
Required materials and conditions: A/B/placebo in the same 34 people, sequence allocation and carryover/period effects
Materials to obtain first: Crossover flow, sequence/period and original analysis model
Further research: When materials are supplemented, distinguish conditions/time points within the same person and crossover assumptions.
Remaining uncertainty: Preparation scope of the stored summary. Sequence-specific n, sequence generation/concealment, washout, carryover, period/sequence models and effective n by condition are unverified.
Conditions for verification: Connect A/B/placebo in the same 34 people, sequence allocation and carryover/period effects to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of A/B/placebo in the same 34 people, sequence allocation and carryover/period effects.
Application exceptions: Do not sum A/B/placebo, repeated time points or two checklists as independent participants/trials.
Referenced methods: M08 §8.1–8.2.3; CHAMGAP adaptation; Distinction between studies and reports in M04 §4.6.1–4.6.2; Cohort/outcome connections are CHAMGAP adaptations

Related sources R01

N08 · What are the common conditions and other exposures?

Current findings: The stored review summary preserves a healthy population and acute comparison of three drinks.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.
Reason for missing information: Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.
Required materials and conditions: Pre-visit caffeine/activity, meals, medication and measurement environment
Materials to obtain first: Pre-visit conditions, concurrent exposure and actual implementation/measurement records
Further research: Record actual common product-comparison conditions and other exposures together in follow-up materials.
Remaining uncertainty: Preparation scope of the stored summary. Pre-visit caffeine/meal/activity restrictions, measurement environment, concurrent exposure and actual condition implementation are unverified.
Conditions for verification: Connect Pre-visit caffeine/activity, meals, medication and measurement environment to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Pre-visit caffeine/activity, meals, medication and measurement environment.
Application exceptions: Do not invent fasting/rest/restriction times or experimental/daily-life procedures absent from the stored review summary.
Referenced methods: M03 §3.2.3, M08 §8.2.2–8.2.3; Chamgap adaptation

Related sources R01

N09 · How were double masking, measurement and interpretation implemented?

Current findings: The original design is described as double-masked, with investigators preparing drinks in identical containers.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.
Reason for missing information: Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.
Required materials and conditions: Roles masked, identical containers and ECG/blood-pressure collection
Materials to obtain first: Masking, measurement/interpretation methods and original collection materials
Further research: Connect actual masking by role and measurement processes to outcomes.
Remaining uncertainty: Preparation scope of the stored summary. Masking/unmasking of participants, staff, ECG readers and analysts, test techniques, equipment and interpretation details are unverified.
Conditions for verification: Connect Roles masked, identical containers and ECG/blood-pressure collection to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Roles masked, identical containers and ECG/blood-pressure collection.
Application exceptions: Do not newly verify masking of all interpretations or absence of measurement errors solely from identical containers or a design label.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources R01

N10 · What are the registration identifier and current registration-content status?

Current findings: NCT03196908 appears in the first existing evidence record and research description. The 2017 citation has no separate registration identifier.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.
Reason for missing information: Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.
Required materials and conditions: 2019 NCT03196908 and registration history/plans
Materials to obtain first: Original 2019 registration/plans and separate 2017 registration/method materials
Further research: If registration materials are provided, distinguish the report, plans and actual reading scope.
Remaining uncertainty: Preparation scope of the stored summary. Registration dates, changes, original plans and current content/results disclosure are unread; the 2017 registration identity is unverified.
Conditions for verification: Connect 2019 NCT03196908 and registration history/plans to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2019 NCT03196908 and registration history/plans.
Application exceptions: Do not copy the 2019 NCT as the 2017 registration identifier or upgrade identifier presence to registration verification/link checks.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a and M04 §4.6.3; Chamgap application

Related sources R01 R02

N11 · What are the bibliographies and source locations of the two reports?

Current findings: R01 is Shah SA et al., 2019, J Am Heart Assoc 8:e011318, PMID 31137991. R02 is Fletcher EA et al., 2017, the same journal 6:e004448, PMID 28446495. There is one evidence group and two citations.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.
Reason for missing information: DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.
Required materials and conditions: Shah 2019, Fletcher 2017, PMIDs and evidence/citations
Materials to obtain first: Original bibliography, full text and registration/population connections for each report
Further research: When bibliography is supplemented, distinguish report identity, original results and change events.
Remaining uncertainty: Preparation scope of the stored summary. DOIs, PMCIDs, 2017 recruitment/result values and current external bibliography are absent from the stored review summary and were not looked up.
Conditions for verification: Connect Shah 2019, Fletcher 2017, PMIDs and evidence/citations to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Shah 2019, Fletcher 2017, PMIDs and evidence/citations.
Application exceptions: Do not create an evidence group absent from the stored summary for R02 or infer DOI/PMCID from article numbers.
Referenced methods: M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

Related sources R01 R02

N12 · What is the scope of investigator overlap and Mayo blood-pressure replication?

Current findings: The stored review summary states that 2017 involved overlapping investigators and was not independent replication; independent Mayo investigators replicated blood pressure only. Limited independent QTc replication is a historical description.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.
Reason for missing information: Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.
Required materials and conditions: Identical/unknown cohorts, author overlap and independent QTc/BP distinction
Materials to obtain first: Authors/institutions, registration, participant families and actual Mayo reports
Further research: Distinguish identical cohorts, investigator overlap, independent institutions and QTc/blood-pressure endpoint replication in new materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual participant overlap/trial relationships between 2017 and 2019 and Mayo bibliography/populations/values are unverified.
Conditions for verification: Connect Identical/unknown cohorts, author overlap and independent QTc/BP distinction to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Identical/unknown cohorts, author overlap and independent QTc/BP distinction.
Application exceptions: Do not equate investigator overlap with an identical cohort or create R03/independent clinical-arrhythmia evidence from unspecified Mayo mentions.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources R01 R02

N13 · What is the original scope of support and disclosed relationships?

Current findings: The original record states University of the Pacific support, no reported energy-drink-company funding and Sachin A. Shah’s expert-witness history in caffeine energy-drink litigation.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.
Reason for missing information: Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.
Required materials and conditions: 2019 university support, unreported company funding and litigation expert-witness history
Materials to obtain first: Original support, product provision, author disclosures and analysis/publication roles for each report
Further research: If disclosures are provided, distinguish reports, support types, external relationships and historical/current scope.
Remaining uncertainty: Preparation scope of the stored summary. Product purchase/provision, analysis/publication support, current contracts/relationships and individual 2017 funding/COI disclosures are unread.
Conditions for verification: Connect 2019 university support, unreported company funding and litigation expert-witness history to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2019 university support, unreported company funding and litigation expert-witness history.
Application exceptions: Do not upgrade university support or unreported company funding to new independence certification, absence of conflicts or identical 2017 support.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources R01 R02

N14 · How are original dates, Korean/English text, corrections, axes and history retained?

Current findings: The reference date is 2026-08-26, corrections are an empty array and deliberation an empty string. Complete stored review text preserves Korean/English content, synthesized summaries, verdict decisions, assessment axes and false flags.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.
Reason for missing information: Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.
Required materials and conditions: 2026-08-26, empty corrections/deliberation and parent/sibling context
Materials to obtain first: Complete original stored review summary and actual correction/change events
Further research: If changed materials arise, distinguish the complete pre-change original, events, versions and separate application.
Remaining uncertainty: Preparation scope of the stored summary. Separate classification information and the primary-failed/secondary-positive indicator are absent from this stored review summary. Empty corrections are not a current external correction/retraction check.
Conditions for verification: Connect 2026-08-26, empty corrections/deliberation and parent/sibling context to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2026-08-26, empty corrections/deliberation and parent/sibling context.
Application exceptions: Do not fill original grades, absences, empty values or historical cross-checks with new values/current completed review.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

Related sources R01 R02

N15 · Which materials were actually read?

Current findings: The complete preserved 2961 JSON and its two existing selections were read for preparation. Reading of each report’s summary is distinguished from unread external originals in each checklist.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.
Reason for missing information: External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.
Required materials and conditions: Complete local JSON summary, report-specific material items and unread external originals
Materials to obtain first: User-provided original materials and actual acquisition/reading records
Further research: Distinguish public availability, access, acquisition, actual reading scope and dates for new materials.
Remaining uncertainty: Preparation scope of the stored summary. External abstracts, full texts, registrations, plans, results/harms and disclosures have not been accessed or acquired; no link checks were performed.
Conditions for verification: Connect Complete local JSON summary, report-specific material items and unread external originals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Complete local JSON summary, report-specific material items and unread external originals.
Application exceptions: Do not convert original citation links, historical paper descriptions or copies into external full-text reading/successful access.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources R01 R02

N16 · Are two checklists/material items distinguished from trials/participants?

Current findings: The two existing questions have different scopes in the same complete stored summary. Connecting R01’s 34 people, A/B/placebo and time-point materials to both checklists creates no new participant or replication trial.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.
Reason for missing information: Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.
Required materials and conditions: s0/s1, two reports, conditions/time points and null unique trial/participant totals
Materials to obtain first: Trial-report-participant-condition-time-point-question relationships
Further research: Connect additional reports by distinguishing identical/different populations, institutions and endpoints.
Remaining uncertainty: Preparation scope of the stored summary. Unique trial count, participant total, actual inter-report cohort overlap and independence are not newly summed or certified.
Conditions for verification: Connect s0/s1, two reports, conditions/time points and null unique trial/participant totals to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of s0/s1, two reports, conditions/time points and null unique trial/participant totals.
Application exceptions: Do not add two checklists/reports/crossover conditions or 34-person values to create an independent total sample.
Referenced methods: M04 §4.6.1–4.6.2 distinguishes studies from reports; cohort/result links are a Chamgap application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; design-specific adaptation is Chamgap’s own design

Related sources R01 R02

N17 · What is connected when new materials become available?

Current findings: The two existing questions are prepared separately in the same seven-column format. Each condition was saved/frozen first, with a separate application timestamp retained.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.
Reason for missing information: No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.
Required materials and conditions: Conditions, originals, observations, corrections, reading and change events
Materials to obtain first: User-provided direct endpoint/denominator/plan, clinical event, correction and harm materials
Further research: Separate actual additions/changes into complete prior originals, events, condition versions/freezing, separate application and current handoff.
Remaining uncertainty: Preparation scope of the stored summary. No new clinical search, calculation, effect/CI, reassessment, independence certification or model/internal content review was performed.
Conditions for verification: Connect Conditions, originals, observations, corrections, reading and change events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Conditions, originals, observations, corrections, reading and change events.
Application exceptions: Original candidate pending/eligibility indications are historical; do not reactivate them as active review/waiting.
Referenced methods: M04 §§4.5 and 4.6.3; limits of the current material conversion follow the review scope and Chamgap design

Related sources R01 R02

N18 · What is the direct definition of clinical arrhythmia?

Current findings: The selected question is “Increased clinical arrhythmia”; the stored review note explicitly states that the four-hour trial did not test clinical arrhythmia.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Arrhythmia types, symptom/ECG verification, assessment criteria, baseline arrhythmia exclusions and occurrence definitions are unverified.
Reason for missing information: Arrhythmia types, symptom/ECG verification, assessment criteria, baseline arrhythmia exclusions and occurrence definitions are unverified.
Required materials and conditions: Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment
Materials to obtain first: Direct clinical-event definitions, verification/adjudication and diagnostic materials
Further research: Retain a proposal to specify event types, verification levels, occurrence times and original populations in clinical-event materials.
Remaining uncertainty: Preparation scope of the stored summary. Arrhythmia types, symptom/ECG verification, assessment criteria, baseline arrhythmia exclusions and occurrence definitions are unverified.
Conditions for verification: Connect Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Actual clinical-arrhythmia types, diagnosis/verification and symptoms/assessment.
Application exceptions: Do not convert QTc prolongation, blood-pressure signals or assumed palpitations into actual arrhythmia diagnoses.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

Related sources R01

N19 · Does the QTc biomarker answer increased event occurrence?

Current findings: QTc is an ECG marker of delayed ventricular repolarization. The parent states that QTc prolongation cannot immediately be called clinical-arrhythmia occurrence.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Connections/validation between biomarker changes and direct arrhythmia occurrence, and occurrence data by population/duration, are unverified.
Reason for missing information: Connections/validation between biomarker changes and direct arrhythmia occurrence, and occurrence data by population/duration, are unverified.
Required materials and conditions: Separation of delayed-repolarization biomarkers and direct clinical events
Materials to obtain first: Direct event follow-up, diagnoses and outcomes separate from exposures/biomarkers
Further research: Retain a proposal to distinguish biomarkers, symptoms and verified events in actual clinical materials.
Remaining uncertainty: Preparation scope of the stored summary. Connections/validation between biomarker changes and direct arrhythmia occurrence, and occurrence data by population/duration, are unverified.
Conditions for verification: Connect Separation of delayed-repolarization biomarkers and direct clinical events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Separation of delayed-repolarization biomarkers and direct clinical events.
Application exceptions: Do not convert biomarker P values/means/the 10-ms assumption into clinical-arrhythmia effects or event counts.
Referenced methods: M03 §3.2.4; internally defined extension boundary; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptation is internally designed

Related sources R01

N20 · Are arrhythmia event counts and at-risk population denominators available?

Current findings: The stored review summary records that arrhythmia, hospitalization and death were not tested. The 34 people are participants in the biomarker crossover trial.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Clinical-arrhythmia numerators, actual at-risk/condition-specific denominators, recurrent/first occurrences and person-time are unverified.
Reason for missing information: Clinical-arrhythmia numerators, actual at-risk/condition-specific denominators, recurrent/first occurrences and person-time are unverified.
Required materials and conditions: Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events
Materials to obtain first: Direct event counts, at-risk/exposure denominators and person/event relationships
Further research: Retain a proposal to distinguish person counts, recurrent events, exposure conditions and risk periods in clinical materials.
Remaining uncertainty: Preparation scope of the stored summary. Clinical-arrhythmia numerators, actual at-risk/condition-specific denominators, recurrent/first occurrences and person-time are unverified.
Conditions for verification: Connect Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Clinical-event numerators, exposure/comparator denominators, baseline disease and recurrent events.
Application exceptions: Do not convert untested outcomes into zero events or copy 34 as a verified arrhythmia denominator.
Referenced methods: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; Design-specific adaptations are designed by CHAMGAP; M19 §19.1.2–19.2.4; CHAMGAP adaptation

Related sources R01

N21 · How do four-hour measurements differ from clinical-risk periods?

Current findings: 2019 measurements occurred every 30 minutes through 240 minutes after intake. The study is not recorded as sufficiently capturing subsequent clinical events.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Continuous event monitoring, emergency/hospitalization follow-up, post-exposure risk windows and long-term follow-up are unverified.
Reason for missing information: Continuous event monitoring, emergency/hospitalization follow-up, post-exposure risk windows and long-term follow-up are unverified.
Required materials and conditions: 240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure
Materials to obtain first: Clinical verification, timing/risk windows and long-term follow-up materials
Further research: Retain a proposal to distinguish measurement times from actual event observation/verification periods.
Remaining uncertainty: Preparation scope of the stored summary. Continuous event monitoring, emergency/hospitalization follow-up, post-exposure risk windows and long-term follow-up are unverified.
Conditions for verification: Connect 240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 240 minutes of acute biomarker measurements, actual event follow-up and long-term exposure.
Application exceptions: Do not convert four-hour test markers into completed clinical-event testing or absence of long-term events.
Referenced methods: Design-specific harm questions in M19 §19.2; Detailed temporal relationships are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP

Related sources R01

N22 · What are the actual contrasts and adjustments for clinical events?

Current findings: Original A/B/placebo comparisons concern QTc and blood pressure. Actual estimates comparing increased clinical arrhythmia are not provided in the stored review summary.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Clinical-event contrasts, baseline risk, caffeine/concurrent-exposure adjustment and crossover/observational-design models are unverified.
Reason for missing information: Clinical-event contrasts, baseline risk, caffeine/concurrent-exposure adjustment and crossover/observational-design models are unverified.
Required materials and conditions: Verified energy-drink-versus-comparator arrhythmia effects and models
Materials to obtain first: Direct clinical comparisons, numerators/denominators and confounding/analysis definitions
Further research: Retain a proposal to connect actual exposure, comparator populations, baseline risk and models with events in clinical materials.
Remaining uncertainty: Preparation scope of the stored summary. Clinical-event contrasts, baseline risk, caffeine/concurrent-exposure adjustment and crossover/observational-design models are unverified.
Conditions for verification: Connect Verified energy-drink-versus-comparator arrhythmia effects and models to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Verified energy-drink-versus-comparator arrhythmia effects and models.
Application exceptions: Do not transfer biomarker A/B pairwise P values or caffeine content to between-condition clinical-event effects.
Referenced methods: M19 §19.2.2–19.2.4, M03 §3.2.3; CHAMGAP adaptation; M08 §8.2.2, M15 §15.3.1; CHAMGAP adaptation

Related sources R01

N23 · Are arrhythmia effects, CIs and power provided?

Current findings: Unreported 95% CIs and the 10-ms assumption in the stored review summary concern between-condition QTc comparisons. Clinical-arrhythmia effects/CIs were not provided.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Direct arrhythmia risk differences/RRs/HRs, CIs, power and minimum important differences are unverified.
Reason for missing information: Direct arrhythmia risk differences/RRs/HRs, CIs, power and minimum important differences are unverified.
Required materials and conditions: Direct clinical-event effects, intervals, denominators and power
Materials to obtain first: Clinical occurrence effects, intervals, actual denominators and plans
Further research: If direct clinical estimates are provided, connect measures, denominators, durations and uncertainty.
Remaining uncertainty: Preparation scope of the stored summary. Direct arrhythmia risk differences/RRs/HRs, CIs, power and minimum important differences are unverified.
Conditions for verification: Connect Direct clinical-event effects, intervals, denominators and power to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Direct clinical-event effects, intervals, denominators and power.
Application exceptions: Do not calculate arrhythmia effects/CIs/risk rates from the QTc 10-ms assumption, ±, P values or n.
Referenced methods: M15 §15.3.1–15.3.3; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are Chamgap design

Related sources R01

N24 · What are the prespecified and actual clinical-arrhythmia collection plans?

Current findings: The original prespecified primary endpoint was QTc; the stored review summary explicitly states that clinical arrhythmia was not tested.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Prespecified arrhythmia endpoints, active/passive collection, surveillance plans, plan dates and actual implementation are unverified.
Reason for missing information: Prespecified arrhythmia endpoints, active/passive collection, surveillance plans, plan dates and actual implementation are unverified.
Required materials and conditions: Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy
Materials to obtain first: Original plans, clinical-event collection/assessment and outcome hierarchy
Further research: Retain a proposal to distinguish prespecified plans from actual collection and the scope of events tested in new materials.
Remaining uncertainty: Preparation scope of the stored summary. Prespecified arrhythmia endpoints, active/passive collection, surveillance plans, plan dates and actual implementation are unverified.
Conditions for verification: Connect Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Event plans, diagnosis, surveillance and primary/supportive/exploratory hierarchy.
Application exceptions: Do not inherit primary QTc or an NCT identifier as prespecified/actually tested clinical arrhythmia.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

Related sources R01

N25 · How do event missingness, non-collection and non-reporting differ?

Current findings: Only the preserved description of untested arrhythmia in a biomarker trial was read this time. External original materials/supplementary tables are unread.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Distinctions among absent event collection, non-reporting, undetermined findings, observation loss and zero events, and direct materials, are unverified.
Reason for missing information: Distinctions among absent event collection, non-reporting, undetermined findings, observation loss and zero events, and direct materials, are unverified.
Required materials and conditions: Actual clinical-event collection, observation loss and reporting level
Materials to obtain first: Clinical collection methods, follow-up flow, omissions/missingness and original tables
Further research: Retain a proposal to distinguish actual non-occurrence of events from absent collection/follow-up in clinical materials.
Remaining uncertainty: Preparation scope of the stored summary. Distinctions among absent event collection, non-reporting, undetermined findings, observation loss and zero events, and direct materials, are unverified.
Conditions for verification: Connect Actual clinical-event collection, observation loss and reporting level to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Actual clinical-event collection, observation loss and reporting level.
Application exceptions: Do not convert currently unread/untested materials into failed access, zero arrhythmias or confirmed increased arrhythmia.
Referenced methods: M08 §8.2.2 and M15 §15.3.1: in-house application; M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4: design-specific adaptation is in-house.

Related sources R01

N26 · Are hospitalization, death and symptoms separate outcomes?

Current findings: The stored review summary states that arrhythmia, hospitalization and death were not directly tested. Symptom-occurrence values were not provided either.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Definitions, denominators and durations for symptoms, verified arrhythmia, emergency care/hospitalization and death are unverified.
Reason for missing information: Definitions, denominators and durations for symptoms, verified arrhythmia, emergency care/hospitalization and death are unverified.
Required materials and conditions: Distinction among arrhythmia, palpitations/symptoms, hospitalization and death
Materials to obtain first: Direct verification, numerators/denominators and risk periods for each clinical outcome
Further research: Retain a proposal to record symptoms, diagnoses, healthcare use and death as separate event outcomes.
Remaining uncertainty: Preparation scope of the stored summary. Definitions, denominators and durations for symptoms, verified arrhythmia, emergency care/hospitalization and death are unverified.
Conditions for verification: Connect Distinction among arrhythmia, palpitations/symptoms, hospitalization and death to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Distinction among arrhythmia, palpitations/symptoms, hospitalization and death.
Application exceptions: Do not assume symptoms to create new events or sum event types into a composite occurrence rate.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; Question-specific outcome adaptations are designed by CHAMGAP; CHAMGAP’s interpretation boundary, informed by M19 principles; no official causality tool was run

Related sources R01

N27 · What are applicability gaps for patients, adolescents and long-term exposure?

Current findings: The original 2019 population comprised healthy adults aged 18–40, excluding disease, hypertension, QT prolongation and regular medication use.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Direct arrhythmia materials for baseline arrhythmia/cardiovascular risk, adolescents, medication/mixed exposure, small doses and repeated/chronic intake are unverified.
Reason for missing information: Direct arrhythmia materials for baseline arrhythmia/cardiovascular risk, adolescents, medication/mixed exposure, small doses and repeated/chronic intake are unverified.
Required materials and conditions: Healthy young people, one high-volume exposure and other risks/durations
Materials to obtain first: Direct clinical occurrence materials by exposure/risk population/duration
Further research: Retain a proposal to distinguish actual risk populations, exposures, durations, concurrent medication and events in clinical materials.
Remaining uncertainty: Preparation scope of the stored summary. Direct arrhythmia materials for baseline arrhythmia/cardiovascular risk, adolescents, medication/mixed exposure, small doses and repeated/chronic intake are unverified.
Conditions for verification: Connect Healthy young people, one high-volume exposure and other risks/durations to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Healthy young people, one high-volume exposure and other risks/durations.
Application exceptions: Do not newly establish/create clinical harms/safety, prevention/treatment or intake-care guidance for populations outside the trial.
Referenced methods: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are Chamgap’s own design; M03 §3.2.1; detailed population conditions are Chamgap’s own design

Related sources R01

N28 · Are earlier QTc and independent blood-pressure descriptions direct arrhythmia replication?

Current findings: 2017 is an earlier bibliography with QTc prolongation direction; Mayo is a description of independent blood-pressure replication. The stored review summary has no independent replication results for direct arrhythmia occurrence.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Actual clinical-event collection, bibliography, samples and verification materials from earlier/separate trials, and independent direct arrhythmia research, are unverified.
Reason for missing information: Actual clinical-event collection, bibliography, samples and verification materials from earlier/separate trials, and independent direct arrhythmia research, are unverified.
Required materials and conditions: Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials
Materials to obtain first: Clinical outcomes and population/institution/registration connections in each actual report
Further research: Retain a proposal to distinguish biomarker replication, institutional independence and direct clinical-event replication in additional materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual clinical-event collection, bibliography, samples and verification materials from earlier/separate trials, and independent direct arrhythmia research, are unverified.
Conditions for verification: Connect Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Separation of 2017 biomarkers, Mayo blood pressure and direct clinical-event materials.
Application exceptions: Do not transfer earlier overlapping-investigator or independent blood-pressure descriptions into independently established increased clinical arrhythmia.
Referenced methods: M04 §4.6.1–4.6.2, M15 §15.3.1; CHAMGAP adaptation; Distinction between studies and reports in M04 §4.6.1–4.6.2; Cohort/outcome connections are CHAMGAP adaptations

Related sources R01 R02

N29 · What is the scope of the original ? grade and untested-outcome note?

Current findings: The selected grade is ?, with the note “The four-hour trial did not test clinical arrhythmia.” Parent D30 biomarker-harm context is retained in its original role.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Direct clinical occurrence, risks/CIs, testing and long-term materials are unverified. This preparation does not assess effects or grades.
Reason for missing information: Direct clinical occurrence, risks/CIs, testing and long-term materials are unverified. This preparation does not assess effects or grades.
Required materials and conditions: Selected clinical-event question, original ? and gap in direct evidence
Materials to obtain first: Direct clinical-event comparison/verification materials and user-provided originals
Further research: If new direct materials are provided, preserve original ? and originals/change events while distinguishing separate judgment and preparation.
Remaining uncertainty: Preparation scope of the stored summary. Direct clinical occurrence, risks/CIs, testing and long-term materials are unverified. This preparation does not assess effects or grades.
Conditions for verification: Connect Selected clinical-event question, original ? and gap in direct evidence to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Selected clinical-event question, original ? and gap in direct evidence.
Application exceptions: Do not copy parent D in place of the selected ? or display the question “Increased clinical arrhythmia” as a confirmed observed conclusion.
Referenced methods: Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed

Related sources R01

H01 · Are biomarkers, harms and clinical-event collection distinguished?

Current findings: Original materials record QTc/BP time changes and no testing of arrhythmia/hospitalization/death. Direct materials for the selected clinical events are unverified.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.
Reason for missing information: Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.
Required materials and conditions: QTc/BP testing, verified clinical events and adverse-event definitions
Materials to obtain first: Collection plans, harm definitions and direct clinical outcome tables
Further research: Retain a proposal to distinguish measured biomarkers, symptoms and verified events in follow-up materials.
Remaining uncertainty: Preparation scope of the stored summary. Complete adverse/serious event lists, collection/relatedness assessment and verified clinical-event lists are unverified.
Conditions for verification: Connect QTc/BP testing, verified clinical events and adverse-event definitions to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of QTc/BP testing, verified clinical events and adverse-event definitions.
Application exceptions: Do not convert biomarker worsening into clinical-event counts or untested outcomes into zero adverse events.
Referenced methods: M19 §19.1.2–19.2.4; Detailed distinctions are designed by CHAMGAP

Related sources R01

H02 · What are harm timing and actual exposure?

Current findings: Research exposure was 946 mL with about 300–320 mg caffeine within one hour; measurements covered 240 minutes.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.
Reason for missing information: Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.
Required materials and conditions: Single research exposure, acute measurement and event-risk periods
Materials to obtain first: Actual exposure, response times and event follow-up/risk windows
Further research: Retain a proposal to distinguish exposure, testing times and clinical-event risk periods in harm materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual completed exposure, individual response times, post-follow-up events and long-term risk periods are unverified.
Conditions for verification: Connect Single research exposure, acute measurement and event-risk periods to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Single research exposure, acute measurement and event-risk periods.
Application exceptions: Do not convert the original exposure into recommended intake, a safe dose or prevention/treatment methods.
Referenced methods: M19 §19.2 design-specific harm questions; timing details are Chamgap-designed

Related sources R01

H03 · How do between-condition biomarker differences differ from clinical harm comparisons?

Current findings: The stored review summary records maximum QTc and blood-pressure time differences, while direct clinical arrhythmia/hospitalization/death comparisons were not tested.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.
Reason for missing information: Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.
Required materials and conditions: Biomarker outcomes for A/B/placebo and clinical-event comparisons
Materials to obtain first: Actual clinical-event comparators, counts and estimates
Further research: Retain a proposal to connect direct harm materials using event definitions, comparisons and intervals separate from biomarkers.
Remaining uncertainty: Preparation scope of the stored summary. Clinical-event contrasts, original numerators/denominators, durations and intervals are unverified.
Conditions for verification: Connect Biomarker outcomes for A/B/placebo and clinical-event comparisons to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker outcomes for A/B/placebo and clinical-event comparisons.
Application exceptions: Do not transfer biomarker P values to clinical-harm P values or between-condition event risks.
Referenced methods: M19 §§19.2.2–19.2.4 and M03 §3.2.3; Chamgap adaptation

Related sources R01

H04 · What are safety and event denominators?

Current findings: The 34 people in the stored review summary are healthy adult crossover-trial participants; separate denominators for each event/safety analysis were not provided.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.
Reason for missing information: Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.
Required materials and conditions: 34 people and actual denominators by condition/time/event
Materials to obtain first: Safety/event denominators, condition-specific flow and original counts
Further research: Retain a proposal to distinguish person, condition, time-point and measurement/event denominators in originals.
Remaining uncertainty: Preparation scope of the stored summary. Condition-specific exposure, measurement, event collection, serious-harm denominators and repeated-observation aggregation are unverified.
Conditions for verification: Connect 34 people and actual denominators by condition/time/event to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 34 people and actual denominators by condition/time/event.
Application exceptions: Do not multiply crossover conditions/time measurements into participant counts or calculate risk rates from unread materials.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation; M08 Table 8.2.a, M15 §15.3 and M19 §§19.1.2–19.2.4; design-specific adaptation is Chamgap-designed

Related sources R01

H05 · What are alternative harm factors and ingredient-specific attribution?

Current findings: Exposure was commercial energy drink with about 300–320 mg caffeine. The stored review summary preserves a whole-product comparison.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.
Reason for missing information: Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.
Required materials and conditions: Caffeine, combined ingredients, baseline/concurrent exposures and relatedness
Materials to obtain first: Original ingredients, concurrent exposures, baseline risk and harm-case assessment
Further research: Retain a proposal to distinguish whole products, ingredient-specific attribution and alternative factors in direct harm materials.
Remaining uncertainty: Preparation scope of the stored summary. Non-caffeine ingredients, composition, other exposures, baseline susceptibility and alternative causes/relatedness assessment for individual events are unverified.
Conditions for verification: Connect Caffeine, combined ingredients, baseline/concurrent exposures and relatedness to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Caffeine, combined ingredients, baseline/concurrent exposures and relatedness.
Application exceptions: Do not attribute every signal to caffeine alone or established harm from a particular ingredient, or invent mechanisms/event cases.
Referenced methods: M19 §§19.2.2–19.2.4 design considerations; detailed confounding records are Chamgap-designed

Related sources R01

H06 · Are unread, untested, unreported and zero events distinguished?

Current findings: Actual reading this time concerns preserved JSON summaries; the original description of untested clinical events is retained.
Verification status: Unverified
Materials actually read: Summary read; external materials not read
Why unverified: Required direct definitions, values and materials are unverified within the current stored-summary/unread-external-material scope. Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.
Reason for missing information: Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.
Required materials and conditions: Actual reading level, untested clinical endpoints and original reports
Materials to obtain first: Original collection plans, complete results, missingness reasons and reading records
Further research: Only for provided materials, connect actual zero events, missingness, non-reporting and non-collection with locations/durations.
Remaining uncertainty: Preparation scope of the stored summary. Distinctions among collection, non-reporting, undetermined findings and actual zero events in external originals, and all harm outcomes, are unverified.
Conditions for verification: Connect Actual reading level, untested clinical endpoints and original reports to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Actual reading level, untested clinical endpoints and original reports.
Application exceptions: Do not convert currently unread materials into zero side effects, failed access, an absent paper or confirmed direct clinical harm.
Referenced methods: M19 §§19.1.2–19.2.4 and M04 §4.6.3; Chamgap adaptation

Related sources R01 R02

H07 · Are harms across reports, conditions and two checklists protected from duplicate counting?

Current findings: Two checklists prepare different existing questions from the same stored 2961 summary. The 2017/2019 bibliographies involve overlapping investigators; actual participant overlap is unverified.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.
Reason for missing information: Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.
Required materials and conditions: 2017/2019, author overlap, conditions/time points and two questions in the same summary
Materials to obtain first: Report-person-condition-time-point-event-question relationships
Further research: Retain a proposal to distinguish repeated reports of the same event from different populations/new events in harm materials.
Remaining uncertainty: Preparation scope of the stored summary. Actual relationships of identical events/people across reports, independent harm families and repeated events by condition are unverified.
Conditions for verification: Connect 2017/2019, author overlap, conditions/time points and two questions in the same summary to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of 2017/2019, author overlap, conditions/time points and two questions in the same summary.
Application exceptions: Do not equate investigator overlap with the same cohort or count two bibliographies/checklists as new independent-event replication.
Referenced methods: M04 §§4.6.1–4.6.2; harm-material adaptation is Chamgap-designed; M04 §§4.6.1–4.6.2 distinction between studies and reports; cohort/outcome links are Chamgap adaptations

Related sources R01 R02

H08 · What are safety gaps for long-term use and vulnerable populations?

Current findings: The parent emphasizes a single high-volume exposure in healthy young adults; the original safety status is Caution.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.
Reason for missing information: Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.
Required materials and conditions: Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents
Materials to obtain first: Direct harms and clinical follow-up by exposure/duration/risk population
Further research: Retain a proposal to record direct materials together with actual exposure, population and observation duration.
Remaining uncertainty: Preparation scope of the stored summary. Direct harm/clinical-event materials for chronic/repeated intake, other doses, adolescents, disease/medication and mixed exposures are unverified within this scope.
Conditions for verification: Connect Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Selected healthy adults, single high-volume exposure and chronic use/patients/adolescents.
Application exceptions: Do not create safe-dose, intake/care, arrhythmia prevention/treatment or medical-replacement procedures.
Referenced methods: M19 §§19.1.2–19.2.4; Chamgap adaptation

Related sources R01

H09 · Are signals distinguished from direct causal or clinical confirmation?

Current findings: Original s0 is D for the no-QTc/BP-effect claim; s1 is ? for increased clinical arrhythmia. Biomarker signals and the gap in direct clinical events are retained separately.
Verification status: Partly verified
Materials actually read: Summary read; external materials not read
Why unverified: Information from the stored summary is connected; this does not mean new clinical verification, fulfilled conditions or completed content review. No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.
Reason for missing information: No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.
Required materials and conditions: Biomarker signals, original D, direct clinical ? and unverified information
Materials to obtain first: Actual biomarker/clinical-event materials, denominators, intervals and verification
Further research: Retain a proposal to distinguish observation, relatedness, direct clinical-effect levels and change events in additional materials.
Remaining uncertainty: Preparation scope of the stored summary. No new benefit/harm assessment, occurrence effect, causal/independence certification or treatment selection was created.
Conditions for verification: Connect Biomarker signals, original D, direct clinical ? and unverified information to actual endpoints, exposures, comparisons, time, denominators and reading levels; distinguish unverified information.
Why this condition is needed: Preparation condition retaining the original scope of Biomarker signals, original D, direct clinical ? and unverified information.
Application exceptions: Do not label original question wording as proven observation or combine biomarkers and clinical events into a new harm assessment.
Referenced methods: Chamgap interpretive boundary informed by M19 principles; no formal causality tool was run

Related sources R01